Fortrea Holdings Inc.
Financials
Valuation Metrics
Fortrea Holdings Inc.'s Market Cap is $1.89B. At end of 2025 it was $1.57B. Ranked #2062 of 3,121 in US market (top 66%), #799 of 1,463 on NASDAQ (top 55%), #144 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 54%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.89B | US#2,062/3,121 Sec#144/266 |
| Revenue | $2.68B | US#1,271/3,121 Sec#34/266 |
| Net Income | $-85M | US—/3,121 Sec—/266 |
| Total Assets | $2.71B | US#1,885/3,121 Sec#48/266 |
| Net Assets | $524M | US#2,208/3,121 Sec#105/266 |
| Employees | 13,871 | US#716/3,121 Sec#23/266 |
| Value | ||
| P/B | 3.60x | US#1,932/3,121 Sec#107/266 |
| P/S | 0.70x | US#485/3,121 Sec#8/266 |
| EV/EBITDA | 34.90x | US#2,282/3,121 Sec#66/266 |
| FCF Yield | 7.99% | US#877/3,121 Sec#28/266 |
| Profitability | ||
| ROE | -16.25% | US#2,449/3,121 Sec#93/266 |
| ROA | -3.14% | US#2,449/3,121 Sec#80/266 |
| Op. Margin | 0.41% | US#2,327/3,121 Sec#80/266 |
| Revenue Growth | -2.09% | US#2,377/3,121 Sec#138/266 |
| Financial Health | ||
| Debt Ratio | 417.91% | US#2,297/3,121 Sec#223/266 |
| Total Debt | $1.12B | US#1,483/3,121 Sec#44/266 |
| FCF | $151M | US#1,544/3,121 Sec#55/266 |
| Cash | $169M | US#1,869/3,121 Sec#126/266 |
| Current Ratio | 0.96x | US#2,330/3,121 Sec#258/266 |
| Net Debt/EBITDA | 11.69x | US#2,391/3,121 Sec#84/266 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,121 Sec—/266 |
| Payout Ratio | 0.00% | US—/3,121 Sec—/266 |
| Performance | ||
| 1Y Return | 87.14% | US#231/3,121 Sec#66/266 |
| 1M Return | 9.87% | US#140/3,121 Sec#16/266 |
| From 52W High | -6.83% | US#322/3,121 Sec#25/266 |
| 1Y MDD | -51.47% | US#2,515/3,121 Sec#187/266 |
| Trading | ||
| Volume | 2,840,765 shares | US#754/3,121 Sec#77/266 |
| Trading Value | $56M | US#1,313/3,121 Sec#99/266 |
| Per Share | ||
| EPS | $-0.90 | US—/3,121 Sec—/266 |
| BPS | $5.54 | US#2,240/3,121 Sec#122/266 |
Company Info
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.